Patent · US Active

Compounds which selectively modulate the CB2 receptor

US8383651B2 · kind B2 · utility

0Cited by

40References

6Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Alessandra Bartolozzi · Norwalk, US
Doris Riether · Biberach an der Riß, DE
Renee M. Zindell · New Milford, US
Patricia Amouzegh · Abingdon, GB
Nigel James Blumire · Biggenden, AU
Monika Ermann · Wantage, GB
Innocent Mushi · Felton, GB
Robert John Scott · Abingdon, GB

Key dates

Filing date	Sep 15, 2010
Grant date	Feb 26, 2013
Priority date	—
Expiry date	Sep 15, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.